Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:12:45 2024-02-27 pm EST 5-day change 1st Jan Change
3.45 USD 0.00% Intraday chart for Rani Therapeutics Holdings, Inc. +4.57% +3.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Rani Therapeutics Holdings, Inc. - Special Call
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111) CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care MT
Rani Therapeutics Stock Climbs After Share Purchase by CEO MT
Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration CI
Rani Therapeutics Reports 'Successful' Oral Delivery of Humira in High-Capacity Pill in Preclinical Study MT
Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study CI
Sector Update: Health Care Stocks Mixed Premarket Monday MT
Rani Therapeutics Starts Early Stage Trial of Autoimmune Disease Treatment Candidate MT
Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43) CI
Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) dropped from S&P Global BMI Index CI
Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies CI
HC Wainwright Adjusts Price Target on Rani Therapeutics to $20 From $22, Keeps Buy Rating MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Rani Therapeutics Holdings, Inc. Appoints Kate Mckinley as Chief Business Officer CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lyn Baranowski, A Member of the Board of Directors of Rani Therapeutics Holdings, Inc. and the Compensation Committee and the Nominating and Corporate Governance Committee, Will Not Stand for Re-Election CI
Transcript : Rani Therapeutics Holdings, Inc., Q4 2022 Earnings Call, Mar 22, 2023
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart Rani Therapeutics Holdings, Inc.
More charts
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. It manufactures and assembles RaniPill capsules at its facility in San Jose, California.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.45 USD
Average target price
11.86 USD
Spread / Average Target
+243.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Rani Therapeutics Holdings, Inc. - Nasdaq
  4. News Rani Therapeutics Holdings, Inc.
  5. Rani Therapeutics Starts Early Stage Trial of Autoimmune Disease Treatment Candidate
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW